Viking Therapeutics :
VKTX
VKTX
Stock Data
$37.08
$0.13 (0.35%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Viking Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. Its leading drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD with a novel approach, aiming for efficacy and safety. Viking is also advancing VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 for metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline aimed at addressing significant unmet medical needs.
All Viking Therapeutics Articles
28 Articles